Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Hiroyuki Okuzawa, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Ari Fujishiro, Corporate Officer,
Head of Investor Relations and Shareholder Relations Department
Telephone: for media +81-3-6225-1126
for stock market participants +81-3-6225-1125

Notice Regarding NTK's Filing of Appeal in Damages Claim Against Daiichi Sankyo

Tokyo, Japan (September 28, 2026) –Daiichi Sankyo Company, Limited (head office: Chuo-ku, Tokyo; hereinafter, "Daiichi Sankyo") hereby announces that, with respect to the lawsuit filed against Daiichi Sankyo by Northern TK Venture Pte. Ltd. (head office: Singapore; hereinafter, "NTK"), a wholly-owned subsidiary of IHH Healthcare Berhad (head office: Malaysia;), the Tokyo District Court rendered a judgment on September 10, 2026, dismissing all of NTK's claims (hereinafter, the "Judgment"), as announced in Daiichi Sankyo's press release dated September 10, 2026, entitled "Daiichi Sankyo Receives Favorable Judgment in Damage Claim Filed by NTK."*

* https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260910_E2.pdf

Daiichi Sankyo hereby announces that it has confirmed that NTK has filed an appeal against the Judgment, as described below.

1. Court Where Appeal Was Filed and Date
   (1) Court where the appeal was filed: Tokyo High Court
   (2) Date of the filing: September 24, 2026

2. Overview of Appellant
   Name: Northern TK Venture Pte. Ltd.
   Address: 1, HARBOURFRONT PLACE, #03-02, HARBOURFRONT TOWER ONE, Singapore 098633
   Position and name of representative: Agarwal Aanchal, Representative Director

3. Cause of Appeal and Proceedings Leading to Appeal
   Based on an arbitral award dated April 29, 2016 against former shareholders of Ranbaxy (hereinafter, the "Arbitration Award"), Daiichi Sankyo has been pursuing enforcement of the Arbitration Award before the courts in India in accordance with Indian law. In the course of those

enforcement proceedings, the tender offer by NTK for Fortis Healthcare Limited (hereinafter, "FHL") was suspended pursuant to a decision by the Supreme Court of India.

NTK filed the lawsuit alleging that it suffered damages, including as a result of the suspension of the tender offer due to Daiichi Sankyo's interference. As stated above, however, the suspension of the tender offer resulted from a decision of the Supreme Court of India made following due process in the course of Daiichi Sankyo's enforcement of the Arbitration Award in India. On September 10, 2026, the Tokyo District Court accepted Daiichi Sankyo's arguments and rendered the Judgment dismissing all of NTK's claims. NTK, being dissatisfied with the Judgment, filed an appeal before the Tokyo High Court

4. Details of Appeal

(1) Claims

(i) Claim for damages

(ii) Claim for injunctive relief against interference with share acquisition, etc.

(iii) Claim for publication of text designated by NTK on Daiichi Sankyo's website and submission of a document with the same content to the Securities and Exchange Board of India

(2) Amount claimed

JPY 203,301,807,840

5. Outlook

Daiichi Sankyo considers that the Judgment rendered by the Tokyo District Court is a fair and appropriate determination. Daiichi Sankyo will continue to assert the legitimacy of its position in the appellate proceedings. With respect to the impact on Daiichi Sankyo consolidated financial results, the matter is currently under review. If any additional matter requiring disclosure arises in connection with this lawsuit, Daiichi Sankyo will promptly make an announcement.

About Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com.